Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Short-term Investments (2021 - 2025)

Caribou Biosciences (CRBU) has disclosed Short-term Investments for 5 consecutive years, with $127.0 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 34.29% to $127.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $127.0 million through Dec 2025, down 34.29% year-over-year, with the annual reading at $127.0 million for FY2025, 34.29% down from the prior year.
  • Short-term Investments for Q4 2025 was $127.0 million at Caribou Biosciences, down from $136.1 million in the prior quarter.
  • The five-year high for Short-term Investments was $277.7 million in Q4 2023, with the low at $127.0 million in Q4 2025.
  • Average Short-term Investments over 5 years is $194.7 million, with a median of $193.2 million recorded in 2024.
  • The sharpest move saw Short-term Investments skyrocketed 46.66% in 2023, then tumbled 34.29% in 2025.
  • Over 5 years, Short-term Investments stood at $135.4 million in 2021, then skyrocketed by 39.81% to $189.3 million in 2022, then skyrocketed by 46.66% to $277.7 million in 2023, then tumbled by 30.4% to $193.2 million in 2024, then crashed by 34.29% to $127.0 million in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $127.0 million, $136.1 million, and $158.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.